Summary & Overview
CPT 93583: Catheter-Based Septal Reduction by Controlled Infarction
CPT code 93583 represents a catheter-based septal reduction procedure that intentionally creates a controlled infarction to reduce abnormally thick interventricular septal muscle causing left ventricular outflow tract obstruction. This targeted cardiology intervention matters nationally as an alternative to surgical myectomy for select patients with obstructive hypertrophic cardiomyopathy, with implications for procedural planning, site-of-service selection, and payer coverage policies. Key payers discussed include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise explanation of the clinical intent and typical care setting for the service, an overview of common modifiers associated with the procedure, and national considerations relevant to billing and reimbursement. The publication outlines expected documentation elements and typical hospital-based sites of service, highlights payer coverage trends and benchmarks where available, and summarizes policy factors that affect adoption and coding practice. Data not available in the input is noted where applicable.
Billing Code Overview
CPT code 93583 describes a catheter-based cardiac intervention to create a controlled infarction in order to reduce an area of abnormally thick heart muscle between the ventricles that is causing an outflow obstruction. The procedure is a targeted, minimally invasive treatment aimed at relieving hypertrophic obstruction by inducing a small, controlled myocardial infarct in the septal tissue.
-
Service type: Catheter-based septal reduction intervention
-
Typical site of service: Hospital inpatient or outpatient cardiac catheterization laboratory or hybrid operating suite
Clinical & Coding Specifications
Clinical Context
A typical patient is a 60-year-old with symptomatic obstructive hypertrophic cardiomyopathy presenting with exertional dyspnea, syncope, or angina refractory to medical therapy. After clinical evaluation including history, physical exam with a systolic murmur, transthoracic and transesophageal echocardiography showing asymmetric septal hypertrophy and a left ventricular outflow tract gradient, and often cardiac MRI to define septal thickness and anatomy, the patient is referred for a catheter-based septal reduction procedure. In the catheterization laboratory, the interventional cardiology team performs a controlled septal infarction by delivering alcohol via a coronary septal perforator branch to induce targeted myocardial necrosis and reduce septal thickness and outflow obstruction. Typical workflow steps include pre-procedure informed consent, coronary angiography to identify suitable septal perforator(s), balloon occlusion and test injection, delivery of absolute alcohol, hemodynamic assessment of gradient reduction, post-procedure monitoring in a cardiac unit with telemetry, and follow-up echocardiography to document gradient and septal remodeling. The typical site of service is an inpatient or outpatient hospital cardiac catheterization laboratory with backup cardiothoracic surgical support available for complications.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
00 | Procedure or service furnished to a medicare beneficiary — No modifier published by CMS with this numeric value for claims; included per input list |